Each year, the annual Myeloma Canada Scientific Roundtable brings together over 80 stakeholders, including Canada's top myeloma experts from coast to coast, scientists from the USA and Europe, our industry research partners and patients. The meeting is an incubator for clinical trial ideas and supports our goal of developing high-impact made-in- Canada clinical trials for patients across the country. The MCRN's clinical trial portfolio continues to grow and with the recent launch of the MCRN Canadian Multiple Myeloma Database, we will now be able to gather patient outcome data from across the country to better identify the optimal treatment approaches.
2016 Scientific Roundtable
On September 16 and 17, Myeloma Canada hosted the 7th annual Myeloma Canada Scientific Roundtable in Montreal. Co-chaired by Dr Tony Reiman from Saint John and Dr Chris Venner from Edmonton, the meeting brought together over 80 stakeholders, including Canada's top myeloma experts from coast to coast, scientists from the USA and Europe, our industry research partners and patients. This year's guest speakers included Dr Ola Landgren from Memorial Sloan Kettering Cancer Center in New York; Dr Antonio Palumbo; Dr Marta Chesi and Dr Leif Bergsagel from the Mayo Clinic in Scottsdale; Dr Noemi Puig from University Hospital in Salamanca, Spain; Dr David Murray from the Mayo Clinic in Rochester; Dr Jonathan Keats from the Translational Genomics Research Institute in Scottsdale; and Dr Don Morris, this year's recipient of the Myeloma Canada/Cancer Research Society Research Grant, from the Tom Baker Cancer Centre in Calgary.
A wide range of current topics in myeloma research were discussed, including minimal residual disease (MRD), genomics, cell therapy, oncolytic viral therapy and individualization of myeloma therapy using risk stratification models.
Additionally, clinical trial ideas incorporating innovative immuno-oncology strategies were discussed resulting in three new MCRN clinical trials that will be further developed.
The meeting is an incubator for clinical trial ideas and supports our goal of developing high-impact made-in-Canada clinical trials for patients across the country. The Scientific Roundtable was a huge success, with each year proving to be better than the last. The highly valuable presentations and topics sparked important discussions, the sharing of ideas and a forward-thinking thought processes.